article thumbnail

Trends in the Clinical Characteristics and Outcome of Infective Endocarditis: A Nationwide Study From 2016 to 2021

Journal of the American Heart Association

This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2016 to 2.59 in 2016 to 15.4%

article thumbnail

Predicting the risk of heart failure after acute myocardial infarction using an interpretable machine learning model

Frontiers in Cardiovascular Medicine

Background Early prediction of heart failure (HF) after acute myocardial infarction (AMI) is essential for personalized treatment. The primary endpoint was the occurrence of HF within 3 years after operation.

article thumbnail

Severe Maternal Grief Associated with Increased Risk of Heart Failure in Child

DAIC

In a new study published in JACC: Heart Failure , maternal loss of a partner or child shortly before or during pregnancy was found to be associated with increased risk of heart failure up to middle-age in the child. According to the World Heart Federation, more than 64 million people worldwide have heart failure.

article thumbnail

AskBio Receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure

DAIC

Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heart failure (CHF), could potentially lead to a therapeutic effect on the heart.1,2

article thumbnail

AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)

DAIC

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heart failure (CHF). Heart failure. 2016:25:2. [5]

article thumbnail

Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction

The New England Journal of Medicine

Treatment options for heart failure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1

article thumbnail

Could Statins Be The Next Breakthrough HFpEF Treatment?

CardiacWire

Statins are one of the most-prescribed drug classes in the world, but there’s still little data on their heart failure benefits, especially for HFpEF patients. The two major RCTs evaluating statins as a heart failure treatment (CORONA and GISSI-HF) didn’t show significant benefits, although they mainly focused on HFrEF patients.